Best of the Week
Most Popular
1. TESLA! Cathy Wood ARK Funds Bubble BURSTS! - 12th May 21
2.Stock Market Entering Early Summer Correction Trend Forecast - 10th May 21
3.GOLD GDX, HUI Stocks - Will Paradise Turn into a Dystopia? - 11th May 21
4.Crypto Bubble Bursts! Nicehash Suspends Coinbase Withdrawals, Bitcoin, Ethereum Bear Market Begins - 16th May 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.Cathy Wood Ark Invest Funds Bubble BURSTS! ARKK, ARKG, Tesla Entering Severe Bear Market - 13th May 21
7.Stock Market - Should You Be In Cash Right Now? - 17th May 21
8.Gold to Benefit from Mounting US Debt Pile - 14th May 21
9.Coronavius Covid-19 in Italy in August 2019! - 13th May 21
10.How to Invest in HIGH RISK Tech Stocks for 2021 and Beyond - Part 2 of 2 - 18th May 21
Last 7 days
Virgin Media Fibre Broadband Installation - What to Expect, Quality of Wiring, Service etc. - 21st Jun 21
Feel the Inflationary Heartbeat - 21st Jun 21
The Green Superfuel That Could Disrupt Global Energy Markers - 21st Jun 21
How Binance SCAMs Crypto Traders with UP DOWN Coins, Futures, Options and Leverage - Don't Get Bogdanoffed! - 20th Jun 21
Smart Money Accumulating Physical Silver Ahead Of New Basel III Regulations And Price Explosion To $44 - 20th Jun 21
Rambling Fed Triggers Gold/Silver Correction: Are Investors Being Duped? - 20th Jun 21
Gold: The Fed Wreaked Havoc on the Precious Metals - 20th Jun 21
Investing in the Tulip Crypto Mania 2021 - 19th Jun 21
Here’s Why Historic US Housing Market Boom Can Continue - 19th Jun 21
Cryptos: What the "Bizarre" World of Non-Fungible Tokens May Be Signaling - 19th Jun 21
Hyperinflationary Expectations: Reflections on Cryptocurrency and the Markets - 19th Jun 21
Gold Prices Investors beat Central Banks and Jewelry, as having the most Impact - 18th Jun 21
Has the Dust Settled After Fed Day? Not Just Yet - 18th Jun 21
Gold Asks: Will the Economic Boom Continue? - 18th Jun 21
STABLE COINS PONZI Crypto SCAM WARNING! Iron Titan CRASH to ZERO! Exit USDT While You Can! - 18th Jun 21
FOMC Surprise Takeaways - 18th Jun 21
Youtube Upload Stuck at 0% QUICK FIXES Solutions Tutorial - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations Video - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations and Trend Analysis into Market Correction - 17th Jun 21
Stocks, Gold, Silver Markets Inflation Tipping Point - 17th Jun 21
Letting Yourself Relax with Activities That You Might Not Have Considered - 17th Jun 21
RAMPANT MONEY PRINTING INFLATION BIG PICTURE! - 16th Jun 21
The Federal Reserve and Inflation - 16th Jun 21
Inflation Soars 5%! Will Gold Skyrocket? - 16th Jun 21
Stock Market Sentiment Speaks: Inflation Is For Fools - 16th Jun 21
Four News Events That Could Drive Gold Bullion Demand - 16th Jun 21
5 ways that crypto is changing the face of online casinos - 16th Jun 21
Transitory Inflation Debate - 15th Jun 21
USDX: The Cleanest Shirt Among the Dirty Laundry - 15th Jun 21
Inflation and Stock Market SPX Record Highs. PPI, FOMC Meeting in Focus - 15th Jun 21
Stock Market SPX 4310 Right Around the Corner! - 15th Jun 21
AI Stocks Strength vs Weakness - Why Selling Google or Facebook is a Big Mistake! - 14th Jun 21
The Bitcoin Crime Wave Hits - 14th Jun 21
Gold Time for Consolidation and Lower Volatility - 14th Jun 21
More Banks & Investors Are NOT Believing Fed Propaganda - 14th Jun 21
Market Inflation Bets – Squaring or Not - 14th Jun 21
Is Gold Really an Inflation Hedge? - 14th Jun 21
The FED Holds the Market. How Long Will It Last? - 14th Jun 21
Coinbase vs Binance for Bitcoin, Ethereum Crypto Trading & Investing During Bear Market 2021 - 11th Jun 21
Gold Price $4000 – Insurance, A Hedge, An Investment - 11th Jun 21
What Drives Gold Prices? (Don't Say "the Fed!") - 11th Jun 21
Why You Need to Buy and Hold Gold Now - 11th Jun 21
Big Pharma Is Back! Biotech Skyrockets On Biogen’s New Alzheimer Drug Approval - 11th Jun 21
Top 5 AI Tech Stocks Trend Analysis, Buying Levels, Ratings and Valuations - 10th Jun 21
Gold’s Inflation Utility - 10th Jun 21
The Fuel Of The Future That’s 9 Times More Efficient Than Lithium - 10th Jun 21
Challenges facing the law industry in 2021 - 10th Jun 21
SELL USDT Tether Before Ponzi Scheme Implodes Triggering 90% Bitcoin CRASH in Cryptos Lehman Bros - 9th Jun 21
Stock Market Sentiment Speaks: Prepare For Volatility - 9th Jun 21
Gold Mining Stocks: Which Door Will Investors Choose? - 9th Jun 21
Fed ‘Taper’ Talk Is Back: Will a Tantrum Follow? - 9th Jun 21
Scientists Discover New Renewable Fuel 3 Times More Powerful Than Gasoline - 9th Jun 21
How do I Choose an Online Trading Broker? - 9th Jun 21
Fed’s Tools are Broken - 8th Jun 21
Stock Market Approaching an Intermediate peak! - 8th Jun 21
Could This Household Chemical Become The Superfuel Of The Future? - 8th Jun 21
The Return of Inflation. Can Gold Withstand the Dark Side? - 7th Jun 21
Why "Trouble is Brewing" for the U.S. Housing Market - 7th Jun 21
Stock Market Volatility Crash Course (VIX vs VVIX) – Learn How to Profit From Volatility - 7th Jun 21
Computer Vision Is Like Investing in the Internet in the ‘90s - 7th Jun 21
MAPLINS - Sheffield Down Memory Lane, Before the Shop Closed its Doors for the Last Time - 7th Jun 21
Wire Brush vs Block Paving Driveway Weeds - How Much Work, Nest Way to Kill Weeds? - 7th Jun 21
When Markets Get Scared and Reverse - 7th Jun 21
Is A New Superfuel About To Take Over Energy Markets? - 7th Jun 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Highly Undervalued Biotechnology Stocks To Watch

Companies / BioTech Aug 28, 2019 - 06:45 AM GMT

By: Joshua_Rodriguez

Companies The biotechnology industry is an exciting one. As continued innovation drives a better scientific understanding of the human body and the ailments that weigh on it, we are seeing better outcomes for patients who are living longer, more fulfilling lives.

However, it’s not only the patients that are seeing tremendous benefit out of this innovation. Investors are benefiting greatly as well. After all, as new medications hit the market, tremendous revenue opportunities are being created for the companies creating these treatments.




Nonetheless, 2019 hasn’t been a great one for the biotechnology industry as a whole.

Nektar Therapeutics (NKTR): Beaten Down YTD But Creating A Compelling Opportunity

Nektar Therapeutics has had an incredibly rough year so far in 2019. Unfortunately, the stock has been cut nearly in half throughout the year. Nonetheless, it is showing incredible promise, and recent declines may be nothing more than a half-off discount.

Nektar Therapeutics is an immuno-oncology company. Their flagship candidate, known as NKTR-214, has the potential to treat several different types of cancer.

With regard to the development of the drug, Nektar Therapeutics partnered with Bristol-Myers Squibb (BMY) after the large pharma player made a $1.85 billion investment in Nektar back in 2018. As part of the deal, Nektar has the potential to receive up to $1.8 billion in milestone payments associated with NKTR-214.

At the moment, there’s a Phase 3 clinical program surrounding the drug in more than 20 indications involving 9 different types of cancer. Not to mention, with a strong focus on lung cancer, the company is addressing high-value indications.

Maybe that’s why analysts seem to be so impressed with the stock. According to Tip Ranks, the average price target on the stock is $40.80, suggesting an upside well over 100%. Even the most bearish of analysts give the stock a price target of $21.00, suggesting upside potential of more than 20%. All in all, the undervaluation here is clear!

AbbVie (ABBV): Tumbles In 2019 With A Strong Recovery Ahead

AbbVie is a massive player in the biotechnology space with a name that’s well known globally. Unfortunately, that name has slipped into the mud a bit in 2019, with year-to-date declines of more than 30%.

The company’s claim to fame is its Humira product. Unfortunately, it’s this product that’s leading to all of the concern. Humira currently generates about 61% of the revenue seen by AbbVie, creating a heavy dependence on the drug’s success.

In October of 2018, biosimilars to Humira found their way onto the European market. This competition has already begun to take part of Humira’s market share. Investors are also concerned about competition in AbbVie’s core market, the United States, as biosimilars have the greenlight to compete in 2023. 

I believe that the concerns with regard to competition are overblown. The truth of the matter is that AbbVie is working on multiple phase 3 clinical studies for a long line of existing drugs. These drugs are likely to see label expansions soon, giving the company more opportunities to expand revenue.

The company also has multiple new drugs in late stages of clinical development. Between two of these, risankizumab and upadacitinib, AbbVie said that it expects to reach revenues of $10 billion annually by 2025.

It’s also worth keeping in mind that the company has several drugs in blockbuster indications that have raked in great sales. Imbruvica, a cancer drug, and Mavyret, a hepatitis C virus drug, are both generating strong revenues.

Although concerns about Humira are rising, investors can’t deny the 16% year-over-year growth in revenue seen in 2018, nor the adjusted EPS growth of 41%. With a market acting on fear and an opportunity that should elicit greed, I believe that AbbVie is primed for strong growth ahead.

Spherix (SPEX): A Small Company With Dynamite Potential

Spherix is by far the smallest company on this list, but it’s definitely not the smallest opportunity. At the moment, the company primarily acts as a hedge fund, making investments in biotechnology companies and reaping the rewards of their growth.

Interestingly, the argument that Spherix is undervalued is very easy to make. Just take a look at the company’s market cap and the book value of the company’s assets. When you do, you’ll see that the company trades on a market cap that represents less than half of the value of its assets.

The book value has seen dramatic growth in recent years. These gains have largely been due to an investment made in Hoth Therapeutics worth about $700,000. Today Hoth Therapeutics is a NASDAQ listed company worth around $50 million. The original ~$700,000 investment is now worth more than $10 million.

The company also made a relatively large investment in CBM recently, purchasing a 20% stake in the oncology-focused biotechnology company. Moving forward, Spherix intends to acquire CBM Biopharma, with a vote expected to take place early next month to decide the fate of the deal.

It’s also worth mentioning that the company recently proposed a dividend worth about $500,000 and intends on proposing more down the road. This is something that you don’t see companies of this stage doing, making it that much more of an eye catcher.

Should all go well, Spherix would immediately become a development-stage biotechnology company with plenty of cash to get through several catalysts. Moreover, considering the fact that the stock has lost nearly a third of its value this year, the opportunity is heavily discounted, making this stock one that’s hard to ignore.

Ligand Pharmaceuticals (LGND): Looked At As Speculative; In Reality, Anything But

Ligand Pharmaceuticals is another stock that has had a pretty rough year. Year to date, the stock has lost nearly a third of its value as analysts largely pass it off as a speculative investment. When you dig into the opportunity, you’ll likely find that it’s anything but.

In my view a large part of the value in Ligand Pharmaceuticals is its business model. While it is a biotechnology company, the company doesn’t actually develop drugs. Well, at least, it doesn’t do it on its own.

The company is focused on developing platforms and licensing them out to drugmakers. These platforms essentially help developers producer new treatments more effectively.

At the moment, Ligand’s technologies are used in 10 different products on the market, inclusive of products from very big names. These technologies are found in Kyprolis by Amgen (AMGN) and Promacta by Novartis (NVS).

To put an end to the speculation conversation, just take a look at the company’s revenues. In 2018, the company generated 78% year-over-year growth. EPS was up more than 10 times on a year-over-year basis.

Moving forward, there are several opportunities to watch for. The company’s technologies are used in 8 late-stage candidates, 21 Phase 2 candidates, and 24 phase 1 candidates. Any positive news out of any of these may act as positive catalysts ahead.

While Ligand has taken a beating so far this year, the stock seems to be doing nothing more than presenting a discount on long-run growth.

Aerie Pharmaceuticals (AERI): Rocklatan Could Quickly Become A Blockbuster

Aerie Pharmaceuticals is another stock that has felt quite a bit of pain this year. The stock is down by almost 40% year to date, but again, this may prove to be a strong opportunity.

Recently, Aerie Pharmaceuticals has announced the regulatory approval of two different treatments; Rhopress was launched in 2018 and Rocklatan was approved in early 2019.

Although Rhopress had a strong start in 2018, the most valuable of these two drugs is Rocklatan, in my view. Indicated as a potential option for patients with glaucoma, the treatment has limited competition in the space.

Considering a strong start with the company’s first drug, Rhopressa, I’m expecting to see more of the same with Rocklatan in an indication that offers up a larger opportunity.

In my view, once sales reports start to show growth in Rocklatan revenues, the stock will start to find its way back up to a more realistic valuation. This is likely why analysts followed by Tip Ranks suggest a potential to see 200% gains based on average price target. All in all, Aerie Pharmaceuticals is a stock that’s well worth watching.

Final Thoughts

While the stocks listed above have lagged behind their peers in the biotech space, I believe that they each represent a strong opportunity. Due to a rough year in 2019, these stocks are trading at incredible discounts. Based on the assets they possess, these discounts shouldn’t last long!

This article is a paid advertisement. View all relevant disclosures here.

By Joshua Rodriguez

© 2019 Copyright Joshua Rodriguez - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in